Skip to main content
SpringerLink
Log in

Cytochrome P450 Drug Interactions Within the HMG-CoA Reductase Inhibitor Class

Are They Clinically Relevant?

  • Leading Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

The present review outlines the clinical relevance of pharmacokinetic drug interactions within the HMG-CoA reductase inhibitor class. These interactions can result in markedly increased or decreased plasma concentrations of some drugs within this class. However, the relationship between altered plasma concentrations and adverse effects or toxicity may not be linear. It is likely that other variables affect this concentration-effect relationship including: rapid changes in the concentration, concomitant lipid-lowering therapy or host genetic factors that code for different forms or amounts of metabolising enzymes and drug receptors.

It is not currently possible to predict which patients will manifest clinically important drug-drug interactions, nor what concentration of an HMG-CoA reductase inhibitor will cause rhabdomyolysis. Thus, until prescribers have better scientific information from which to develop a ‘therapeutic range’ for each agent, caution should be exercised. In particular, patients taking a CYP3A4-metabolised agent, e.g. atorvastatin, simvastatin and lovastatin, should not be started on a CYP3A4 inhibitor or inducer without close monitoring.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme a reductase inhibitors. Arch Intern Med 2000; 160: 2273–80

    Article  PubMed  CAS  Google Scholar 

  2. McCormick AD, Butters CJ. ZD4522: an HMG-CoA reductase inhibitor free of metabolically medicated drug interactions: metabolic studies in human in vitro systems. 29th Annual Meeting of the American College of Clinical Pharmacology; 2000 Sep 17-19; Chicago (IL), 2002

  3. Azie N, Brater BC, Becker P, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64(4): 369–77

    Article  PubMed  CAS  Google Scholar 

  4. Yeo KR. Yeo WW. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 2001; 51(5): 461–70

    Article  PubMed  CAS  Google Scholar 

  5. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64(2): 177–82

    Article  PubMed  CAS  Google Scholar 

  6. Kantola T, Neuvonen P. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998; 64: 58–65

    Article  PubMed  CAS  Google Scholar 

  7. Neuvonen P, Kantola T, Kivisto K. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63(3): 332–41

    Article  PubMed  CAS  Google Scholar 

  8. Kivisto K, Kantola T, Neuvonen P. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46: 49–53

    Article  PubMed  CAS  Google Scholar 

  9. Kantola T, Neuvonen P. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63: 387–402

    Article  Google Scholar 

  10. Lilja J, Neuvonen P. Grapefruit juice - simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998; 64: 477–83

    Article  PubMed  CAS  Google Scholar 

  11. Schmassmann-Suhijar D, Bullingham R, Gasser R, et al. Rhabdomyolysis due to interaction of simvastatin with mibafredil. Lancet 1998; 351: 1929–30

    Article  PubMed  CAS  Google Scholar 

  12. Kent J. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2001; 355(9207): 911–8

    Article  Google Scholar 

  13. Martin J, Fay M. Cytochrome P450 drug interactions: are they clinically relevant? Australian Prescriber 2001; 24(1): 10–2

    Google Scholar 

  14. Davidson M. Statin drug interactions in the elderly. J Cardiovasc Pharmacol Ther 2001; 6(3): 219–29

    Article  PubMed  CAS  Google Scholar 

  15. Sugimoto K, Ohmori M, Tsuruka S, et al. Different effects of St John’s Wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70(6): 518–24

    Article  PubMed  CAS  Google Scholar 

  16. Hsyu P H, Schultz-Smith M, Lillibrisge J, et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001; 45(12): 3445–50

    Article  PubMed  Google Scholar 

  17. Ruschitzka F, Meier P, Turina M, et al. Acute heart transplant rejection due to Saint John’s wort [letter]. Lancet 2000; 35 (9203): 548–9

    Article  Google Scholar 

  18. Lees R. Rhabdomyolysis from the co-administration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995; 333: 644–5

    Article  Google Scholar 

  19. Beaird S. HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. J Am Pharm Assoc 2000; 40: 637–44

    CAS  Google Scholar 

  20. Horn M. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. Arch Dermatol 1996; 132: 1254–5

    Article  PubMed  CAS  Google Scholar 

  21. Ahmad S. Diltiazem myopathy. Am Heart J 1993; 126: 1494–5

    Article  PubMed  CAS  Google Scholar 

  22. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7–22

    Google Scholar 

  23. Rodriguez JA, Paniagua MJ, Crespo-Leiro MG, et al. Rhabdomyolysis with HMG Co-A reductase inhibitors after heart transplant: incidence and prognosis [poster]. Presented at the European Society of Cardiology Congress; 1998 Aug 22-26; Vienna

  24. Keogh A, Macdonald P, Aboyoun C, et al. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000; 19: 529–37

    Article  PubMed  CAS  Google Scholar 

  25. Barclay P, O’Connell P. Clarithromycin drug interactions complicating cyclosporin and simvastatin therapy [letter]. Aust J Hosp Pharm 1996; 26: 180

    Google Scholar 

  26. Corpier C, Jones P, Suki W, et al. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. J Am Med Assoc 1988; 260(2): 239–41

    Article  CAS  Google Scholar 

  27. Maltz H, Balog D, Cheigh J. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother 1999; 33: 1176–9

    Article  PubMed  CAS  Google Scholar 

  28. Muck W, Mai I, Fritsche L, et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 1999; 65: 251–61

    Article  PubMed  CAS  Google Scholar 

  29. Regazzi M, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporine A in transplant recipients. Transplant Proc 1993; 25: 2732–4

    PubMed  CAS  Google Scholar 

  30. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin but not pravastatin in blood of cyclsporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62: 311–21

    Article  PubMed  CAS  Google Scholar 

  31. Goldberg R, Roth O. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996; 62: 1559–64

    Article  PubMed  CAS  Google Scholar 

  32. Gruer P, Vega J, Mercuri M, et al. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999; 84: 811–5

    Article  PubMed  CAS  Google Scholar 

  33. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atherosclerosis 2002; Suppl.3: 35–40

    Google Scholar 

  34. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of the 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1–34

    Article  PubMed  CAS  Google Scholar 

  35. Spach D, Clark C, Burke W. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991; 154: 213–5

    PubMed  CAS  Google Scholar 

  36. Ayanian J, Fuchs C, Stone R. Lovastatin and rhabdomyolysis [letter]. Ann Intern Med 1998; 1009: 682–3

    Google Scholar 

  37. Heerey A, Barry M, Kelly A. The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 2000; 169(3): 176–9

    Article  PubMed  CAS  Google Scholar 

  38. Jacobson R, Wang P, Glueck C. Myositis and rhabdomyolysis associated with current use of simvastatin and nefazodone [letter]. JAMA 1997; 277: 296–7

    Article  PubMed  CAS  Google Scholar 

  39. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998 Nov 5; 339 (19): 1349–57

    Google Scholar 

  40. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995 Nov 16; 333(20): 1301–7

    Article  PubMed  CAS  Google Scholar 

  41. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996 Oct 3; 335(14):1001–9

    Article  PubMed  CAS  Google Scholar 

  42. Pfeffer M, Keech A, Cobbe S, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) project. Circulation 2002; 105: 2341–6

    Article  PubMed  CAS  Google Scholar 

  43. Furber C Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiavasc Med 2001; 2: 205–7

    Article  Google Scholar 

  44. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001; 57: 356–64

    Article  Google Scholar 

  45. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22(6): 441–57

    Article  PubMed  CAS  Google Scholar 

  46. Wen X, Wang J, Backman J, et al. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 2001; 29: 1359–61

    PubMed  CAS  Google Scholar 

  47. Prueksaritanont T, Zhao J, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301: 1042–51

    Article  PubMed  CAS  Google Scholar 

  48. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94: 13–20

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest directly relevant to the content of this manuscript.

Dr Henry Krum is a consultant to the pharmaceutical industry.

Author information

Authors and Affiliations

  1. Clinical Pharmacology Unit, Monash Medical School/Alfred Hospital, Commercial Rd, Prahran, 3181, VIC, Victoria, Australia

    Jennifer Martin

  2. NHMRC Centre of Clinical Research Excellence in Therapeutics, Monash University/ Alfred Hospital, Prahran, Victoria, Australia

    Henry Krum

Authors
  1. Jennifer Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henry Krum
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer Martin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martin, J., Krum, H. Cytochrome P450 Drug Interactions Within the HMG-CoA Reductase Inhibitor Class. Drug-Safety 26, 13–21 (2003). https://doi.org/10.2165/00002018-200326010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200326010-00002

Keywords

Search

Navigation